| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
ELTX
Elicio Therapeutics
|
Apr 15, 2026 | BUY |
Buy
+380.1% avg upside
11 analysts
|
$20.00
419.44% Upside
|
-9.8% |
|
IKT
Inhibikase Therapeutics
|
Mar 04, 2026 | BUY |
Strong Buy
+231.2% avg upside
8 analysts
|
$4.00
118.51% Upside
|
-11.3% |
|
AKTX
Akari Therapeutics
|
Jan 05, 2026 | BUY |
Strong Buy
+957.3% avg upside
7 analysts
|
$40.00
265.69% Upside
|
+24.4% |
|
URGN
Urogen Pharma
|
Nov 07, 2025 | BUY |
Strong Buy
+13.4% avg upside
16 analysts
|
$55.00
63.93% Upside
|
+41.2% |
|
IMUX
Immunic
|
Oct 16, 2025 | BUY |
Strong Buy
+166.2% avg upside
21 analysts
|
$30.00
111.28% Upside
|
+69.8% |
|
KALA
KALA BIO
|
Jul 11, 2025 | BUY |
Strong Buy
+5814.9% avg upside
9 analysts
|
$600.00
16520.59% Upside
|
-99.1% |
|
CAPR
Capricor Therapeutics
|
Mar 20, 2025 | BUY |
Strong Buy
+68.4% avg upside
12 analysts
|
$48.00
69.19% Upside
|
+102.6% |
|
ARDX
Ardelyx
|
Mar 07, 2025 | BUY |
Strong Buy
+124.7% avg upside
21 analysts
|
$11.00
81.88% Upside
|
+16.8% |
|
BDRX
Biodexa Pharmaceuticals
|
Jan 02, 2025 | BUY |
Strong Buy
+488.3% avg upside
1 analyst
|
$18.00
488.33% Upside
|
-94.0% |
|
CLRB
Cellectar Biosciences
|
Dec 05, 2024 | BUY |
Strong Buy
+2960.9% avg upside
7 analysts
|
$390.00
13878.57% Upside
|
-90.8% |
|
CMPX
Compass Therapeutics
|
Nov 13, 2024 | BUY |
Strong Buy
+372.3% avg upside
19 analysts
|
$7.00
246.44% Upside
|
+4.1% |
|
CRVS
Corvus Pharmaceuticals
|
Nov 13, 2024 | BUY |
Strong Buy
+114.4% avg upside
14 analysts
|
$24.00
101.42% Upside
|
-9.8% |
|
MRKR
Marker Therapeutics
|
Oct 21, 2024 | BUY |
Strong Buy
+994.1% avg upside
9 analysts
|
$19.00
1328.53% Upside
|
-71.9% |
|
ACRV
Acrivon Therapeutics, Inc.
|
Sep 16, 2024 | BUY |
Strong Buy
+818.9% avg upside
13 analysts
|
$16.00
919.17% Upside
|
-81.2% |
|
PMVP
PMV Pharmaceuticals
|
Aug 14, 2024 | BUY |
Strong Buy
+1207.4% avg upside
12 analysts
|
$7.00
519.52% Upside
|
+6.9% |
|
CGTX
Cognition Therapeutics
|
Jul 30, 2024 | BUY |
Strong Buy
+305.1% avg upside
9 analysts
|
$5.00
244.92% Upside
|
+28.0% |
|
CLDI
Calidi Biotherapeutics
|
Jun 27, 2024 | BUY |
Strong Buy
+6314.1% avg upside
3 analysts
|
$10.00
5820.75% Upside
|
-89.2% |
|
ZSQR
Z Squared
|
Jun 17, 2024 | HOLD |
Buy
-61.5% avg upside
2 analysts
|
— | · |
|
SLS
SELLAS Life Sciences Group
|
May 16, 2024 | BUY |
Strong Buy
+768.3% avg upside
15 analysts
|
$6.00
25.45% Downside
|
+10.9% |
|
RNTX
Rein Therapeutics
|
Apr 18, 2024 | BUY |
Strong Buy
+1064.9% avg upside
5 analysts
|
$19.00
1974.95% Upside
|
-66.0% |
|
SPRB
Spruce Biosciences
|
Mar 14, 2024 | HOLD |
Strong Buy
+90.8% avg upside
14 analysts
|
— | -58.7% |
|
ANEB
Anebulo Pharmaceuticals
|
Feb 15, 2024 | BUY |
Buy
+796.5% avg upside
5 analysts
|
$4.00
924.61% Upside
|
-49.0% |
|
TPST
Tempest Therapeutics
|
Nov 10, 2023 | BUY |
Buy
+1662.1% avg upside
18 analysts
|
$10.00
713.01% Upside
|
-66.1% |
|
NVCT
Nuvectis Pharma
|
Nov 09, 2023 | BUY |
Strong Buy
+32.3% avg upside
6 analysts
|
$21.00
51.90% Upside
|
+31.4% |
|
ZURA
Zura Bio
|
Oct 10, 2023 | BUY |
Strong Buy
+289.3% avg upside
12 analysts
|
$10.00
166.60% Upside
|
-43.3% |
|
ATHE
Alterity Therapeutics
|
Jun 05, 2023 | BUY |
Strong Buy
+68.0% avg upside
5 analysts
|
$10.00
104.83% Upside
|
-36.2% |
|
PALI
Palisade Bio
|
May 16, 2023 | BUY |
Strong Buy
+1347.1% avg upside
15 analysts
|
$240.00
12734.26% Upside
|
-73.1% |
|
QNRX
Quoin Pharmaceuticals
|
Mar 10, 2023 | HOLD |
Strong Buy
+661.3% avg upside
7 analysts
|
— | -80.3% |
|
MTVA
MetaVia
|
Dec 07, 2022 | BUY |
Strong Buy
+1767.5% avg upside
13 analysts
|
$6.00
274.91% Upside
|
-63.1% |
|
NXTC
NextCure
|
Nov 04, 2022 | HOLD |
Buy
+753.8% avg upside
10 analysts
|
— | -40.4% |
|
ALLR
Allarity Therapeutics
|
Aug 23, 2022 | HOLD |
Buy
+581.7% avg upside
2 analysts
|
— | -99.9% |
|
ANVS
Annovis Bio
|
May 02, 2022 | BUY |
Strong Buy
+1309.5% avg upside
7 analysts
|
$37.00
2014.32% Upside
|
+38.9% |
|
REGN
Regeneron
|
Nov 09, 2021 | HOLD |
Strong Buy
+26.9% avg upside
57 analysts
|
— | +20.5% |
|
NKTR
Nektar Therapeutics
|
Nov 08, 2021 | BUY |
Strong Buy
+16.6% avg upside
25 analysts
|
$20.00
67.16% Downside
|
-74.1% |
|
IONS
Ionis Pharmaceuticals
|
Oct 21, 2021 | HOLD |
Strong Buy
+13.3% avg upside
43 analysts
|
— | +48.2% |
|
INCY
Incyte
|
Sep 23, 2021 | BUY |
Buy
+1.0% avg upside
47 analysts
|
$89.00
9.31% Downside
|
-4.1% |
|
VYGR
Voyager Therapeutics
|
Sep 20, 2021 | BUY |
Strong Buy
+284.7% avg upside
23 analysts
|
$9.00
141.89% Upside
|
+103.0% |
|
DCOY
Decoy Therapeutics
|
Aug 06, 2021 | BUY |
Strong Buy
+343.7% avg upside
7 analysts
|
$5.00
17.73% Downside
|
· |
|
SCPS
Scopus BioPharma
|
Jul 01, 2021 | BUY |
Strong Buy
+4999900.0% avg upside
1 analyst
|
$20.00
4999900.04% Upside
|
· |
|
PCSA
Processa Pharmaceuticals
|
Jun 21, 2021 | BUY |
Strong Buy
+1996.9% avg upside
5 analysts
|
$15.00
607.48% Upside
|
-59.5% |
|
INO
Inovio Pharmaceuticals
|
Jan 08, 2021 | BUY |
Buy
+808.5% avg upside
19 analysts
|
$15.00
1245.27% Upside
|
-50.0% |
|
NBIX
Neurocrine
|
Sep 30, 2020 | HOLD |
Strong Buy
+7.8% avg upside
37 analysts
|
— | -0.3% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.